These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Review of NIHRAC focuses on gene therapy. Fox JL Biotechnology (N Y); 1995 May; 13(5):431-2. PubMed ID: 9634783 [No Abstract] [Full Text] [Related]
23. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial. Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455 [TBL] [Abstract][Full Text] [Related]
24. Genetic testing to provide targeted treatment for cystic fibrosis patients. Edelman A; Sermet-Gaudelus I; Rousset JP Pharmacogenomics; 2007 Sep; 8(9):1101-4. PubMed ID: 17924824 [No Abstract] [Full Text] [Related]
25. Status of gene therapy for cystic fibrosis lung disease. Boucher RC J Clin Invest; 1999 Feb; 103(4):441-5. PubMed ID: 10021450 [No Abstract] [Full Text] [Related]
38. Development of adeno-associated virus vectors for gene therapy of cystic fibrosis. Carter BJ; Flotte TR Curr Top Microbiol Immunol; 1996; 218():119-44. PubMed ID: 8794249 [No Abstract] [Full Text] [Related]
40. Department of Health and Human Services. Recombinant DNA Advisory Committee. National Institutes of Health. Minutes of Meeting. June 14, 1999. Hum Gene Ther; 2000 Jun; 11(9):1369-82. PubMed ID: 11032449 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]